Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer
Brief Summary: This trial will compare the efficacy and toxicity of standard first-line chemotherapy alone vs. standard chemotherapy plus sorafenib in patients with stage III/IV ovarian cancer following cytoreductive surgery. Patients with residual large volume disease and/or bowel involvement will be excluded, to minimize the risk of bowel perforation.


Options:
A: Arm Label: Paclitaxel/Carboplatin/Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin
B: Arm Label: Arm I (carboplatin and paclitaxel); Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm II (oxaliplatin and capecitabine); Type: EXPERIMENTAL; Interventions: Drug: Capecitabine, Other: Laboratory Biomarker Analysis, Drug: Oxaliplatin, Other: Quality-of-Life Assessment | Arm Label: Arm III (carboplatin, paclitaxel, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Carboplatin, Other: Laboratory Biomarker Analysis, Drug: Paclitaxel, Other: Quality-of-Life Assessment | Arm Label: Arm IV (oxaliplatin, capecitabine, bevacizumab); Type: EXPERIMENTAL; Interventions: Biological: Bevacizumab, Drug: Capecitabine, Other: Laboratory Biomarker Analysis, Drug: Oxaliplatin, Other: Quality-of-Life Assessment | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm III (carboplatin, paclitaxel, bevacizumab), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Arm II (oxaliplatin and capecitabine), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm III (carboplatin, paclitaxel, bevacizumab) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm II (oxaliplatin and capecitabine), Arm III (carboplatin, paclitaxel, bevacizumab), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Oxaliplatin; Assigned to Arm(s): Arm II (oxaliplatin and capecitabine), Arm IV (oxaliplatin, capecitabine, bevacizumab) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm III (carboplatin, paclitaxel, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (carboplatin and paclitaxel), Arm II (oxaliplatin and capecitabine), Arm III (carboplatin, paclitaxel, bevacizumab), Arm IV (oxaliplatin, capecitabine, bevacizumab)
C: Arm Label: Ovarian cancer; Type: EXPERIMENTAL; Interventions: Drug: Oral rucaparib | Intervention Type: DRUG; Name: Oral rucaparib; Assigned to Arm(s): Ovarian cancer
D: Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD 40mg/m2 ivgtt q4w | Arm Label: PLD + Apatinib; Type: EXPERIMENTAL; Interventions: Drug: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w +Apatinib 250mg po qd; Assigned to Arm(s): PLD + Apatinib | Intervention Type: DRUG; Name: PLD 40mg/m2 ivgtt q4w; Assigned to Arm(s): PLD

Answer: A